The global elastography imaging market is on a robust growth trajectory, with the market size expected to increase from US$4.6 billion in 2025 to US$7.5 billion by 2032, reflecting a compound annual growth rate (CAGR) of 7.2% during the forecast period. This expansion is primarily driven by a rising preference for non-invasive, cost-effective imaging solutions that offer high diagnostic accuracy without the risks associated with tissue biopsies.
Elastography imaging is now a critical component in modern diagnostic workflows, particularly in the management of chronic liver diseases, breast cancer, and musculoskeletal disorders. Its ability to measure tissue stiffness makes it valuable for disease staging and therapy monitoring, thereby enhancing clinical decision-making. The growing clinical trust and technological advancements in this space underscore its pivotal role in the future of diagnostic imaging.
Key Industry Highlights
North America is expected to retain the largest market share of approximately 35.7% in 2025, driven by favorable Medicare reimbursement frameworks, widespread CPT code allocation, and broad-scale adoption of high-end ultrasound and MR elastography systems.
Europe is poised to become the fastest-growing region, buoyed by national screening initiatives and updated EASL guidelines recommending elastography as a frontline diagnostic tool for fibrosis and liver health.
A 2025 clinical study in the Egyptian Journal of Radiology and Nuclear Medicine revealed that shear-wave elastography has significant potential for monitoring liver iron overload in pediatric β-thalassemia patients, reinforcing elastography’s application beyond conventional liver fibrosis assessment.
Ultrasound-based elastography is projected to dominate the modality segment, accounting for 70.1% of the global share in 2025, largely due to its affordability, portability, and real-time diagnostic capability.
In terms of application, general imaging is expected to lead with a 33.8% share, reflecting the technology’s utility in assessing liver, thyroid, breast, and musculoskeletal systems across both inpatient and outpatient settings.
Get a Sample Copy of Research Report (Use Corporate Mail id for Quick Response): https://www.persistencemarketresearch.com/samples/35570
Market Dynamics
Driver – Rising Burden of Chronic Liver Disease and Breast Cancer Spurs Demand
The surging incidence of chronic liver conditions, particularly Non-Alcoholic Fatty Liver Disease (NAFLD), Hepatitis B, and C, is a primary driver behind elastography adoption. In Europe, elastography has become a standard diagnostic procedure in hepatology units, with biopsy rates declining by up to 40% due to the efficiency of non-invasive stiffness assessment.
Additionally, elastography’s role in breast cancer diagnostics is gaining prominence, especially in populations with dense breast tissue where traditional mammography is less effective. Its ability to differentiate between benign and malignant lesions through stiffness quantification is a vital clinical asset in early cancer detection strategies.
Restraint – Technical Challenges in Obese Patients Limit Reliability
Despite the clear benefits, elastography imaging faces limitations in patients with high body mass index (BMI). The presence of excess adipose tissue can impair signal penetration and reduce the accuracy of stiffness measurements, particularly in liver and breast imaging.
A 2023 multicenter study published in Hepatology Communications identified a 15% failure rate in elastography among obese patients, necessitating repeat scans or reverting to invasive biopsies. These limitations pose a challenge for hospitals aiming for standardization across diverse patient demographics.
Opportunity – Multi-modality Platforms Strengthen Oncology Diagnostics
The convergence of ultrasound elastography and Magnetic Resonance Elastography (MRE) presents a compelling opportunity for healthcare providers to enhance diagnostic precision. Multi-modality imaging allows for cross-validation of results, particularly useful in oncology, where tissue characterization requires high confidence.
As personalized medicine gains traction, multi-modal platforms can offer layered insights into tissue pathology, aiding both diagnosis and longitudinal treatment tracking. MRE, in particular, is gaining traction in pharmaceutical trials, where reproducible biomarkers are essential for endpoint evaluation.
Category-wise Analysis
Modality Insights
Ultrasound-based elastography continues to dominate, accounting for over 70% of global market share in 2025. The popularity of this modality stems from its low capital cost, broad system compatibility, and ease of integration into existing ultrasound workflows. Hospitals are increasingly opting for software-based elastography upgrades, accelerating penetration in mid-tier and rural settings.
Meanwhile, Magnetic Resonance Elastography is establishing its niche in high-resolution organ imaging with greater reproducibility. It is especially relevant for clinical trials in NAFLD and MASH, where accurate, whole-organ stiffness assessment is vital for regulatory compliance and patient monitoring.
Application Insights
The general imaging segment is set to hold 33.8% of the total market, demonstrating elastography’s cross-functional use across organ systems. From liver and thyroid imaging to musculoskeletal evaluations, elastography enables broad diagnostic applicability with a single investment, appealing to resource-conscious providers.
Breast imaging is emerging as a strong growth segment. In countries like Japan and India, where mammographic screening of women under 40 is limited, elastography is being adopted as a first-line tool. The method’s ability to detect suspicious lesions in dense tissue offers a compelling case for its inclusion in national screening protocols.
Request for Customization of the Research Report: https://www.persistencemarketresearch.com/request-customization/35570
Regional Insights
North America
North America’s leadership is reinforced by well-defined reimbursement codes under Medicare and Medicaid. The U.S. maintains a dual framework supporting both shear-wave ultrasound and MR elastography, ensuring that elastography is a staple across hepatology, radiology, and oncology departments.
CMS policies allow hospitals to integrate elastography without reimbursement friction, positioning the region as a stable market with ongoing innovation in AI integration and remote diagnostics.
Europe
Europe’s market is characterized by country-specific adoption strategies, with France positioning transient elastography as a routine tool in hepatology. The UK and Germany prefer shear-wave techniques integrated into multipurpose ultrasound systems for broader clinical use.
The 2024 EASL guideline revision has acted as a major catalyst, particularly in Italy and Spain, where public hospitals are expanding elastography capabilities to align with non-invasive fibrosis assessment mandates.
Asia Pacific
Asia Pacific is the fastest-expanding market, led by China, where domestically developed platforms are enabling price competition and broadening adoption. The FT9000 system, for instance, has matched FibroScan on core metrics while reducing cost barriers.
Japan continues to lead in research applications, with elastography used in clinical trials and tertiary diagnostics. Meanwhile, in India, elastography is increasingly integrated into metro-based private hospitals, albeit with challenges in rural penetration.
Competitive Landscape
The elastography imaging market is highly competitive, with global imaging leaders and specialist firms shaping its evolution. Industry giants such as GE Healthcare, Philips, Siemens Healthineers, and Canon Medical Systems dominate the premium segment by bundling AI-enhanced elastography into advanced imaging platforms.
Smaller players are carving out niches in liver health and portable diagnostics, focusing on affordable point-of-care devices and cloud-based analytics. The entry of portable ultrasound elastography systems is redefining frontline care, especially in resource-constrained environments.
Recent Developments
In August 2025, Sonic Incytes Medical Corp received FDA 510(k) clearance for Velacur ONE, a portable point-of-care elastography system tailored for liver diagnostics, highlighting the industry’s move toward decentralization.
In April 2025, Philips launched the Elevate Platform for its EPIQ Elite ultrasound system, enabling remote monitoring, AI-assisted image acquisition, and enhanced collaboration between care teams through virtual consultation modules.
Key Players
Canon Medical Systems Corporation
FUJIFILM Corporation
Esaote SpA
Mindray Bio-Medical Electronics Co., Ltd.
Koninklijke Philips N.V.
Hitachi, Ltd.
GE Healthcare
Toshiba America Medical Systems, Inc.
Siemens AG
Samsung Medison Co., Ltd.
Market Segmentation
By Modality: Ultrasound, Magnetic Resonance
By Application: General Imaging, Hepatology, Breast, Cardiology, Nephrology, Orthopedics, Musculoskeletal
By Region: North America, Europe, Asia Pacific, Latin America, Middle East & Africa
By End User: Hospitals, Diagnostic Imaging Centers, Research Institutes, Ambulatory Surgical Centers
Future Outlook
The elastography imaging market is expected to transition from a niche diagnostic solution to a mainstream clinical standard over the next decade. With the integration of AI, cloud imaging platforms, and remote diagnostic tools, elastography will likely form a cornerstone of non-invasive precision medicine strategies globally.
As clinical trials seek reproducible endpoints and health systems aim to reduce procedure-related complications, elastography offers a compelling value proposition. Investment in multi-modality integration and portable imaging platforms will further expand the reach of elastography into primary care, telemedicine, and emerging markets.
